Form 4: Ionis Pharmaceuticals Director Joseph Loscalzo Receives Annual Equity Compensation

Ionis Pharmaceuticals, Inc. Director Joseph Loscalzo was granted non-qualified stock options and restricted stock units as part of his annual equity compensation, totaling no more than $450,000 for 2025.

Summary

• Joseph Loscalzo, a Director at Ionis Pharmaceuticals, Inc. (IONS), received equity compensation on July 1, 2025.
• The compensation included 11,518 non-qualified stock options with an exercise price of $39.94 per share.
• Additionally, 5,220 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• These grants were adjusted to ensure the non-employee Director's annual equity compensation for 2025 does not exceed $450,000, based on the aggregate grant date fair value as determined by FASB Topic ASC 718.
• The stock options and RSUs are set to vest 100% on the first anniversary of the grant date (July 1, 2026) or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier.
• The stock options expire on June 30, 2035.
• RSUs will be delivered to the reporting person on July 15th following their vesting date.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing detailing director compensation, which is a neutral event. It reflects standard corporate governance practices without indicating any significant positive or negative operational or financial news.

Positives

• Granting of equity compensation to a non-employee director aligns their interests with those of shareholders, promoting long-term value creation.
• The compensation policy includes a cap of $450,000 for annual equity compensation, indicating a structured approach to director remuneration.

Future Outlook

This document is a routine disclosure of director equity compensation and does not provide specific forward-looking statements or guidance regarding the company's business operations or financial performance. It indicates the company's ongoing practice of compensating non-employee directors with equity.

Management Comments

• Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

Industry Context

The practice of compensating non-employee directors with equity, such as stock options and restricted stock units, is a common and widely accepted corporate governance practice across various industries, including biotechnology and pharmaceuticals. This approach aims to align the interests of directors with those of shareholders, encouraging long-term value creation and responsible oversight.

Comparison to Industry Standards

• The use of stock options and restricted stock units for non-employee director compensation is a standard practice across publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• The specific cap of $450,000 for annual equity compensation for non-employee directors is within the typical range observed for companies of similar size and market capitalization in the biotech industry, though specific benchmarks vary widely. For example, companies like Biogen Inc. or Gilead Sciences, Inc. also utilize equity-based compensation for their non-employee directors, with total compensation packages often reflecting company size, performance, and industry norms.
• The vesting schedule, typically one year or until the next annual meeting, is also a common structure designed to retain directors and ensure their continued engagement.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term shareholder value. The compensation policy's cap also provides transparency and limits potential dilution from director equity awards.
• Employees: No direct impact on employees is indicated by this director compensation filing.

Next Steps

• Vesting of the granted stock options and Restricted Stock Units on July 1, 2026, or the next regularly scheduled annual meeting of stockholders, whichever is earlier.
• Delivery of vested Restricted Stock Units to the reporting person on July 15th following the vesting date.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Joseph Loscalzo, Director Compensation, Stock Options, Restricted Stock Units, Equity Compensation, SEC Form 4, Corporate Governance, Non-Employee Director